Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04166409 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
Minor3 versionsRe-verified since Apr 4, 2026, no change to tracked fieldsv423-v425
MinorSite contacts updated at 1 of 132 sitesv422
MinorSite details revised at 1 of 132 sitesv421
Minor2 versionsRe-verified since Mar 31, 2026, no change to tracked fieldsv419-v420
MinorSite contacts updated at 1 of 132 sitesv418
Minor12 versionsRe-verified since Mar 12, 2026, no change to tracked fieldsv406-v417
MinorSite details revised at 2 of 132 sitesv405
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping tumor cells from growing and dividing and may kill them. The overall goal of this study is to see if selumetinib works just as well as the standard treatment of CV for patients with LGG. Another goal of this study is to compare the effects of selumetinib versus CV in subjects with LGG to find out which is better. Additionally, this trial will also examine if treatment with selumetinib improves the quality of life for subjects who take it.